cyrilzakka/clinical-trials huggingface dataset:
Screening for Swallowing Problems in Patients Following Prolonged Intubation: Validation of the Toronto Bedside Swallowing Screening Test (TOR-BSST©)

Despite medical advances, half of the patients admitted to hospital for recovery from acute illness, injury or surgery have swallowing difficulties and those requiring tubes for breathing support are at even greater risk. Difficulties with swallowing decrease patients' quality of life, prolong their hospital stay, as well as lead to medical complications such as pneumonia, malnutrition and death. Presently, there is no screening test for swallowing difficulties in patients who have required respiratory support. Screening will allow for early detection of swallowing problems which is important to prevent serious complications, such as pneumonia. This research will determine the accuracy of a new screening test, the Toronto Bedside Swallowing Screening Test (TOR-BSST©) previously tested with stroke patients, to predict the presence of swallowing difficulties in patients who have required breathing support for longer than 48 hours. The investigators will enroll 100 patients from the intensive care medical surgical units at the University Health Network. The findings from this research will help identify those patients with swallowing problems earlier than it is currently possible. Once identified, at risk patients will be referred to a speech language pathologist swallowing expert for more comprehensive testing; thereby, decreasing their risk of experiencing serious complications, such as pneumonia, secondary to swallowing problems.


Eligibility Criteria:
Inclusion Criteria:

* Adults 18+ years
* Inpatient at University Health Network, in any of the medical-surgical intensive care units, regardless of disease type, comorbidities or previous medical history
* Received endotracheal intubation lasting 48 hours or longer

Exclusion Criteria:

* History of one or more of the following: neurological disorder, surgery to the head or neck, previous oropharyngeal dysphagia, tracheotomy in situ or dementia
The Quality of Life of Patients With Severe Illnesses

Lately researchers and clinicians have emphasized the health related quality of life. Several reasons account for this trend. First of all, the advanced medical practices have contributed to the increased life expectancy. Secondly, the pattern of diseases has shifted from high acuity to chronicity. Therefore, the effectiveness of health care could not be solely evaluated by the rates of morbidity and mortality. The state of patients' quality of life has become the pivotal indicator of the effectiveness of health care interventions. On the other hand, patients' subjective perceptions of health care are crucial factors in treatment processes. Therefore quality of life becomes reference in choosing health care interventions to enhance the benefits of patients.

The scopes of quality of life research include the essence of quality of life, the measurements of quality of life and the relationships between quality of life and its related factors, etc. The local researchers have long put efforts in quality of life research. The results of these studies have contributed to the understandings of different patients' quality of life. However, the majority of studies have focused on specific diseases. This study propose to extend the scope of quality of life research to study patients' quality of life of two severe illnesses, i.e. HIV infections and schizophrenia. These two illnesses represent two severe physical and psychiatric illnesses. Even their etiology, mechanisms, disease process, signs and symptoms, and treatments are different. However, the similarities of these two illnesses include both are severe illnesses without cure, both are stigmatized by the society. Patients with these two illnesses suffer in their personal lives, social relations and quality of life. Therefore the current study to further investigate and compare and contrast the essence of patients' quality of life and their related factors.

The proposed study is a second year study of the two-year study - The quality of life of patients with severe illnesses (NSC93-2314-B-002-294). The first year study focused on the investigation of the quality of life of patients with HIV infections (NSC93-2314-B-002-294). The aim of this proposed study is to compare and contrast the quality of life and its related factors of patients with schizophrenia and HIV infections. The contributions of this study include the in-depth understandings of quality of life of patients with HIV infections and schizophrenia and the comparison of quality of life of different illnesses. The results serve as the foundations in future development of intervention programs to enhance patients' quality of life and cost-effectiveness analyses.


Eligibility Criteria:
Inclusion Criteria:

* people with schizophrenia
* people with HIV

Exclusion Criteria:

-
HepC Micro-elimination on MSM and TGW Population.

This is an observational study, in which a single visit will be carried out, which includes a questionnaire on sexual habits and in which the possibility of carrying out a screening for Hepatitis C will be offered. Depending on the score obtained in the questionnaire, the screening will be carried out using a rapid serology test or viral load. During the first year, a SCORE will be developed to classify the risk of positive results. This SCORE will be used during phase 2 to offer users of the centres a targeted screening based on the Pre-test score.


Eligibility Criteria:
Inclusion Criteria:

1. All BCN Checkpoint and BCN PreP·Point clients.
2. 18 years and older.
3. HIV uninfected or diagnosticated in the center in the last 7 days prior to the study inclusion.
4. Men that have sex with men or transgender women.
5. Signature of written consent form.
6. Ability to comply with the requirements of the study protocol.

Exclusion Criteria:

1. Knowledge of HIV infection from more than 7 days
2. Knowledge of active HCV infection
Yang Yin Fu Zheng Jie Du Therapy in HBV Associated Hepatocellular Carcinoma Based on the Platelet Count/Splenic Length-Diameter Ratio

Clinical research of Yang Yin Fu Zheng Jie Du therapy in HBV associated Hepatocellular Carcinoma based on the platelet count/splenic length-diameter ratio.The purpose of this study is to establish the efficacy evaluation system combined with platelet/splenic length-diameter ratio, and to clarify the effect of this method on relieving hepatitis B cirrhosis and delaying the progression of Hepatocellular Carcinoma.


Eligibility Criteria:
Inclusion Criteria:

Meet the criteria of hepatocellular carcinoma Patients who tested positive for hepatitis B surface antigen (HBsAg) for \>6 months Liver function grade child-Pugh A/B Patients who have agreed to select local treatment according to the Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2017) TCM syndrome differentiation belongs to deficiency of qi and Yin, stasis and toxin accumulation syndrom Informed consent from the patient.

Exclusion Criteria:

Patient with other hepatitis virus infections or alcoholic liver, autoimmunity liver, primary biliary cirrhosis, genetic metabolic liver disease, and previous liver transplantation; Serious problem of heart, lung, brain, blood and other important organs; Patients with metastatic liver cancer; Pregnant or child breast feeding women; Mental or cognitive disorders; Who are allergic to the study drug.
Comorbid Insomnia and Sleep Disordered Breathing in Patients Undergoing Cardiac Rehabilitation

The purpose of this research is to determine how frequently sleep disorders such as sleep disordered breathing and insomnia occur in patients with coronary artery disease enrolled in cardiac rehabilitation. By reviewing results of a variety of tests, we also hope to learn more about the cardiovascular effects on people who may have these conditions.

Patients referred to the Mayo Clinic Rochester CR and meeting eligibility criteria (see Subjects section below) will be recruited and consented. Prior to beginning CR, enrolled patients will undergo baseline sleep and CV assessment at the Clinical Research and Trials Unit (CRTU). Home-based sleep monitoring will take place. Patients will also complete additional cardiometabolic and behavioral evaluation as part of the standard CR clinical care. Following completion of the 12-week CR program, a post-CR assessment may be conducted, including the same set of tests/procedures. All patients will be followed up for at least 6-months following enrollment to monitor cardiac recurrence, hospitalization and death.

Eligibility Criteria:
Inclusion Criteria:

* Patients will be \>18 years old
* Referred to CR following admitted to the hospital with a documented diagnosis of acute coronary syndrome
* Referred to CR following admission to the hospital with a documented diagnosis of ST- elevation myocardial infarction (STEMI),
* Referred to CR following admission to the hospital with a documented diagnosis of non- STEMI
* Referred to CR following admission to the hospital with a documented diagnosis of unstable angina
* Referred to CR following admission to the hospital with a documented diagnosis of post coronary artery bypass surgery
* Referred to CR following admission to the hospital after percutaneous coronary intervention (with or without stent placement).

Exclusion Criteria:

* heart failure with reduced ejection fraction
* peripheral artery disease
* valve or pericardial surgery
* heart transplantation
* patients unable to provide informed consent
* patients unable to speak and read English
* night shift workers
* pregnant women
* those who will only attend full home-based CR.
A Trial Evaluating the Efficacy and Safety of the Sublingual Sufentanil Tablet 30 mcg for Post-Operative Pain After Abdominal Surgery

The purpose of this study is to compare the efficacy and safety of the sublingual Sufentanil Tablet (ST) 30 mcg to the sublingual Placebo Tablet (PT) for the short-term management of moderate-to-severe acute post-operative pain in patients after abdominal surgery.


Eligibility Criteria:
Inclusion Criteria (additional criteria not specified here):

1. Patients who are scheduled to undergo one of the following procedures with general anesthesia or spinal anesthesia that does not include intrathecal opioids during the operation:

   * abdominoplasty
   * open tension-free inguinal hernioplasty (Lichenstein repair with mesh)
   * laparoscopic abdominal surgery
2. Patients classified as American Society of Anesthesiologists (ASA) class I - III (Appendix I).
3. Female patients of childbearing potential must be using an effective method of birth control at the time of screening visit
4. Patients who are expected to have moderate-to-severe post-operative pain for at least 24 hours.

Exclusion Criteria (additional criteria not specified here):

1. Patients who have taken an opioid for more than 30 consecutive days, at a daily dose of more than 15 mg of morphine (or equivalent), within the past 3 months prior to surgery
2. Patients who are currently taking monoamine oxidase inhibitors (MAOIs) or have taken MAOIs within 14 days of the first dose of study drug.
3. Patients with current sleep apnea that has been documented by a sleep laboratory study or are on home continuous positive airway pressure (CPAP).
4. Patients who previously have had abdominoplasty or have had an inguinal hernia repair on the same side.
A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B

To describe liver enzyme elevations in patients who are coinfected with HIV and either Hepatitis C (HCV) and/or Hepatitis B (HBV) receiving maraviroc or placebo in combination with their current suppressive anti-HIV drug therapy.


Eligibility Criteria:
Inclusion Criteria:

* HIV coinfected with HCV and/or HBV.
* Undetectable HIV-1 RNA for at least 3 months prior to the screening visit
* Treatment with current antiretroviral therapy (3-6 drugs excluding low-dose ritonavir) for at least 5 months.

Exclusion Criteria:

* Currently receiving maraviroc.
* Active opportunistic infections.
* ALT and/or AST \>5x upper limit of normal.
* Direct bilirubin \>1.5x upper limit of normal.
* Severe or decompensated liver disease.
* Liver disease unrelated to viral hepatitis infection.
Evaluation of the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of E2609 in Healthy Subjects

The purpose of this single-center, randomized, double-blind, placebo-controlled, study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of E2609 when administered to healthy elderly subjects.


Eligibility Criteria:
Key Inclusion Criteria:

* Healthy males and females
* Female subjects must be of non-childbearing potential
* Aged 50 to 85 years, inclusive BMI of 18 to 32 kg/m2 at screening
* Thyroid function tests within normal rangeMini-Mental State Examination score of 28-30, inclusive

Key Exclusion Criteria:

* History of neurological abnormalities, including seizures
* Any clinically significant abnormality of the ECG at Screening and Baseline including QTc prolongation
* History of ischemic heart disease, cardiac arrhythmias, cerebrovascular diseases
* Other medical conditions that are not stably controlled
* Presence of orthostatic hypotension
A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye

The purpose of this study is to assess the safety and efficacy of Tavilermide Ophthalmic Solution compared with Placebo Ophthalmic Solution in treating the signs and symptoms of dry eye.


Eligibility Criteria:
Inclusion Criteria:

Be at least 18 years of age Provided written informed consent Have a reported history of dry eye Have a history of use or desire to use eye drops for dry eye

Exclusion Criteria:

Be diagnosed with an ongoing ocular infection (bacterial, viral, or fungal), or active ocular inflammation (e.g. follicular conjunctivitis) at Visit 1, or have been diagnosed with ocular rosacea, or any viral or bacterial disease of the cornea or conjunctiva, within the last 12 months Have any planned ocular and/or lid surgeries over the study period Have corrected visual acuity greater than or equal to +0.7 as assessed by Early Treatment of Diabetic Retinopathy Study (ETDRS) scale in both eyes at Visit 1 Have an uncontrolled systemic disease Be a woman who is pregnant, nursing or planning a pregnancy Be a woman of childbearing potential who is not using an acceptable means of birth control; acceptable methods of contraception include: hormonal - oral, implantable, injectable, or transdermal contraceptives; mechanical - spermicide in conjunction with a barrier such as a diaphragm or condom; IUD; or surgical sterilization of partner. For non-sexually active females, abstinence may be regarded as an adequate method of birth control; however, if the subject becomes sexually active during the study, she must agree to use adequate birth control as defined above for the remainder of the study Have a known allergy and/or sensitivity to the test article or its components Have a condition or be in a situation which the investigator feels may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study Be currently enrolled in an investigational drug or device study or have used an investigational drug or device within 45 days of Visit 1 Be unable or unwilling to follow instructions, including participation in all study assessments and visits
Parental Feeding Styles and Child Dietary Quality

In this study, the investigators will use an existing data set to examine the relationship between parent feeding styles and the quality of the dinner meal using the Healthy Eating Index.

Investigators will use an existing data set collected between 2007 and 2009. The purpose of the larger data set including 177 families was to examine parent - child interactions during dinner meals in low-income Hispanic and African-American families participating in Head Start programs. Data was collected on parent-child interactions and information regarding the food served and consumed by children during dinner meals. The specific aims included: 1) examining the overall diet quality using the Healthy Eating Index of Head Start preschool dinner meals by parent feeding styles, an 2) the diet quality of the dinner meal served to that of the meal consumed and within each of the parent feeding styles.

Eligibility Criteria:
Inclusion Criteria:

* Parents who were responsible for feeding the child while the child was not in Head Start and their oldest child enrolled in Head Start.

Exclusion Criteria:

* Any children who have dietary restraints or food allergies.
AF Ablation for HF With Reduced EF

This is an open label, multi-center, randomized parallel control clinical trial, to examining thethe clinical outcomes of AF ablation on HFrEF patients with persistent atrial fibrillation.

This is an open label, multi-center, randomized parallel control clinical trial. HFrEF patients with persistent atrial fibrillation are 1:1 randomized into the AF ablation group or the medical therapy (rate or rhythm control) group. Markers of HFrEF severity, including composite of death from any cause or worsening of heart failure that led to an unplanned overnight hospitalization,exercise hemodynamics, natriuretic peptide levels, and patient symptoms. and other indicators are analyzed to demonstrate the role of AF ablation in comparing the effects of AF ablation vs usual medical therapy for HFrEF patients with persistent atrial fibrillation.

Eligibility Criteria:
Inclusion Criteria:

* Symptomatic persistent atrial fibrillation Failure or intolerance of antiarrhythmic drug therapy or unwillingness to take antiarrhythmic drugs Left Ventricular Ejection Fraction \<= 40% NYHA \>= II Patient is willing and able to comply with the protocol and has written informed consent Age \>= 18 years Optimal therapy for HF of ≥6 weeks Suitable candidate for catheter ablation or rate control for the treatment of AF N-terminal pro-B-type natriuretic peptide (NT-proBNP)/BNP levels above predetermined levels based on prior hospitalization and baseline rhythm

Exclusion Criteria:

* LA dimension \>6.0 cm Acute coronary syndrome, cardiac surgery, angioplasty or stroke within 2 months prior to enrollment Untreated hypothyroidism or hyperthyroidism Enrollment in another investigational drug or device study Woman currently pregnant or breastfeeding or not using reliable contraceptive measures during fertility age Mental or physical inability to take part in the study Severe aortic or mitral valve disease Life expectancy \<1 year
Study on Recurrent Breast Cancer and Repeated Radiation Therapy

This study explores whether recurrent breast cancer can be safely treated with breast-conserving surgery and repeated radiation therapy in cases where patients have previously undergone radiation. Traditionally, recurrent breast cancer has been treated by removing the entire breast. However, recent research has shown that in certain situations, it may be possible to preserve the breast.

The study will collect data on the safety of this treatment approach and its effects on patients. The treatment follows standard breast cancer care practices, involving 30 patients from Helsinki and Turku University Hospitals. Patients are carefully selected based on specific criteria, such as tumor size, localization, and prior treatment history. Special attention is given to the planning of radiation therapy and surgical techniques.

The goal is to develop new treatment strategies that allow breast preservation even in cases of recurrent breast cancer, providing patients with high-quality and individualized care.


Eligibility Criteria:
Inclusion Criteria:

* The patient has a diagnosed breast cancer or tumor area in the breast with a maximum diameter of 3 cm, where a previous breast-conserving surgery has been performed (either invasive breast cancer or carcinoma in situ, DCIS).

The patient has only a local recurrence, and imaging studies show no suspicion of metastases outside the breast (preoperative staging N0M0).

At least 3 years have passed since the completion of prior radiation therapy. The new breast cancer can be technically treated with another breast-conserving surgery using a technique that does not require tissue transfer from areas opposite the removed tumor to restore the shape of the breast.

The patient is at least 55 years old at the time of surgery. The patient is willing to participate in the study. The patient is capable of providing informed consent.

Exclusion Criteria:

* A booster dose, also known as a "boost," was administered during prior radiation therapy.

Preoperative assessments suggest multifocal breast cancer, with the tumor area to be removed exceeding 3 cm.

The planned radiation therapy per the study protocol cannot be administered due to factors such as shoulder joint stiffness, a pacemaker located in the radiation field, or a skin condition (e.g., scleroderma).

The patient is unable to provide informed consent or is unwilling to participate in the study.

Metastases outside the breast (e.g., axillary or distant metastases) are present.
Computer-Assisted HIV Prevention for Young Drug Users

In this study, the investigators are developing and evaluating an interactive, computer-assisted HIV, STD and disease prevention program for young substance abusers that incorporates effective components of both prevention science and educational technologies.

Adolescents and young adults who use drugs are at high risk for infection with HIV, STDs and other diseases with similar transmission dynamics. Although several age-appropriate and effective HIV, STD and disease prevention efforts have been identified for young substance abusers, most interventions have been narrow in focus and are generally not structured to readily address changing patterns of drug use among adolescents that place them at risk for infection with these diseases. In this study, we are developing and evaluating an interactive, computer-assisted HIV, STD and disease prevention program for young substance abusers that incorporates effective components of both prevention science and educational technologies. We plan to develop this program with the input from the target population of adolescents and young adults. We also plan to conduct a randomized, controlled trial to evaluate the benefit of including this program in HIV and disease prevention efforts with youth in substance abuse treatment. In so doing, we will evaluate the ability of the program to promote accurate knowledge about HIV and other diseases, promote self-efficacy to reduce risk behavior and change actual rates of risk behavior among young substance abusers. This computer-based program will be designed to promote the increased adoption of effective HIV and disease prevention science for this population. New information about changing patterns of drug use and HIV risk behaviors can be readily incorporated into the program as it becomes available. The program can be easily exported and able to be applied with fidelity. Importantly, the program will be structured such that a therapist or educator may customize the program content for use by various sub-populations of substance-abusing adolescents and young adults. Thus, the program will be able to address risk factors specific to each young drug user. This program may address many of the challenges associated with the current delivery of evidence-based HIV prevention programs to this population.

Eligibility Criteria:
Inclusion Criteria:

* Aadolescents in outpatients substance abuse treatment
* Ages 13 - 18 years
* Within first month of treatment entry

Exclusion Criteria: